You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm recently described circumstances in which the fraction of host or donor DNA could be altered, and plans new approaches to data interpretation.
The ELISA-based test, which has CE marking, uses protein signatures in blood to detect the onset of kidney disease in type 2 diabetics.
The collaboration in particular focuses on the UK market introduction of SphingoTec's point-of-care tests for use of novel biomarkers in critical care.
An early version of the test is being used by researchers as part of the NIH-funded Chronic Renal Insufficiency Cohort (CRIC) study.
KidneyIntelX is designed to help assess the risk of progressive decline in kidney function in patients with type 2 diabetes and chronic kidney disease.
The financing round was led by Asian private investment firm AT Capital and early-stage deep-tech venture capital fund Elev8.vc.
The London-based firm hopes to also show the clinical utility of its KidneyIntelX assay for predicting the risk of the patients' progressive kidney decline.
The proceeds from the round will allow the firm to begin selling its in vitro diagnostic blood test for patients with chronic kidney disease.
The firm intends to use about $25 million to $30 million of the net proceeds for the continued development and planned commercialization of its KidneyIntelX platform.
The company said it anticipates using about $25 million to $30 million of the net proceeds for the continued development of its KidneyIntelX platform.